image
Basic Materials - Chemicals - Specialty - NYSE - US
$ 20.74
-1.94 %
$ 14.1 B
Market Cap
46.09
P/E
1. INTRINSIC VALUE

Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies.[ Read More ]

The intrinsic value of one AVTR stock under the base case scenario is HIDDEN Compared to the current market price of 20.7 USD, Avantor, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AVTR

image
FINANCIALS
6.97 B REVENUE
-7.26%
696 M OPERATING INCOME
-38.38%
321 M NET INCOME
-53.23%
870 M OPERATING CASH FLOW
3.13%
-144 M INVESTING CASH FLOW
-31.11%
-844 M FINANCING CASH FLOW
-30.06%
1.71 B REVENUE
0.68%
125 M OPERATING INCOME
-32.83%
57.8 M NET INCOME
-37.78%
245 M OPERATING CASH FLOW
-12.91%
-40.5 M INVESTING CASH FLOW
9.80%
-199 M FINANCING CASH FLOW
-0.76%
Balance Sheet Decomposition Avantor, Inc.
image
Current Assets 2.38 B
Cash & Short-Term Investments 280 M
Receivables 1.15 B
Other Current Assets 955 M
Non-Current Assets 10.6 B
Long-Term Investments 50.1 M
PP&E 858 M
Other Non-Current Assets 9.68 B
Current Liabilities 1.48 B
Accounts Payable 626 M
Short-Term Debt 260 M
Other Current Liabilities 594 M
Non-Current Liabilities 6.24 B
Long-Term Debt 5.37 B
Other Non-Current Liabilities 875 M
EFFICIENCY
Earnings Waterfall Avantor, Inc.
image
Revenue 6.97 B
Cost Of Revenue 4.6 B
Gross Profit 2.36 B
Operating Expenses 1.51 B
Operating Income 696 M
Other Expenses 375 M
Net Income 321 M
RATIOS
33.93% GROSS MARGIN
33.93%
10.00% OPERATING MARGIN
10.00%
4.61% NET MARGIN
4.61%
6.11% ROE
6.11%
2.48% ROA
2.48%
5.08% ROIC
5.08%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avantor, Inc.
image
Net Income 321 M
Depreciation & Amortization 402 M
Capital Expenditures -146 M
Stock-Based Compensation 40.5 M
Change in Working Capital 16.6 M
Others 311 M
Free Cash Flow 724 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avantor, Inc.
image
Wall Street analysts predict an average 1-year price target for AVTR of $26.9 , with forecasts ranging from a low of $25 to a high of $28 .
AVTR Lowest Price Target Wall Street Target
25 USD 20.54%
AVTR Average Price Target Wall Street Target
26.9 USD 29.84%
AVTR Highest Price Target Wall Street Target
28 USD 35.00%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Avantor, Inc.
image
Sold
0-3 MONTHS
88.3 K USD 1
3-6 MONTHS
273 K USD 1
6-9 MONTHS
687 K USD 3
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 05, 2024
Sell 88.3 K USD
Eck Steven W
SVP & Chief Accounting Officer
- 3525
25.06 USD
3 months ago
Jul 30, 2024
Sell 270 K USD
Couturier Christophe
EVP, AMEA
- 10000
27 USD
3 months ago
Jul 31, 2024
Sell 2.8 K USD
Couturier Christophe
EVP, AMEA
- 100
28 USD
8 months ago
Mar 08, 2024
Sell 94.4 K USD
Eck Steven W
SVP & Chief Accounting Officer
- 3685
25.63 USD
8 months ago
Feb 29, 2024
Sell 120 K USD
Bramwell James
EVP Sales, Customer Excellence
- 4910
24.52 USD
8 months ago
Feb 29, 2024
Sell 321 K USD
Couturier Christophe
EVP, AMEA
- 13074
24.53 USD
8 months ago
Feb 27, 2024
Sell 152 K USD
Bramwell James
EVP Sales, Customer Excellence
- 6203
24.49 USD
1 year ago
Sep 07, 2023
Sell 156 K USD
Eck Steven W
SVP & Chief Accounting Officer
- 7577
20.64 USD
1 year ago
Aug 25, 2023
Sell 537 K USD
Vanderhaegen Frederic
EVP, Americas and Europe
- 25000
21.47 USD
1 year ago
Apr 11, 2023
Sell 31.7 K USD
Couturier Christophe
EVP, AMEA
- 1498
21.18 USD
1 year ago
Mar 03, 2023
Sell 97.8 K USD
Brophy Gerard
EVP, Biopharma Production
- 3914
25 USD
1 year ago
Feb 27, 2023
Sell 76.5 K USD
Brophy Gerard
EVP, Biopharma Production
- 3059
25 USD
1 year ago
Feb 28, 2023
Sell 56.5 K USD
Couturier Christophe
EVP, AMEA
- 2324
24.32 USD
1 year ago
Feb 23, 2023
Sell 74.6 K USD
Couturier Christophe
EVP, AMEA
- 3078
24.24 USD
1 year ago
Feb 22, 2023
Sell 462 K USD
Couturier Christophe
EVP, AMEA
- 19160
24.12 USD
1 year ago
Feb 02, 2023
Sell 284 K USD
Brophy Gerard
EVP, Biopharma Production
- 11339
25.06 USD
2 years ago
Nov 16, 2022
Bought 259 K USD
Szlosek Thomas A
EVP & CFO
+ 12500
20.708 USD
2 years ago
Nov 16, 2022
Bought 314 K USD
Stubblefield Michael
CEO
+ 15000
20.95 USD
2 years ago
May 20, 2022
Sell 613 K USD
Brophy Gerard
EVP, Biopharma Production
- 19603
31.27 USD
2 years ago
May 23, 2022
Sell 1.23 M USD
Vanderhaegen Frederic
EVP, Americas & Europe
- 39000
31.61 USD
2 years ago
Mar 01, 2022
Sell 69.9 K USD
Brophy Gerard
EVP, Biopharma Production
- 2027
34.47 USD
2 years ago
Feb 23, 2022
Sell 103 K USD
Brophy Gerard
EVP, Biopharma Production
- 3059
33.79 USD
2 years ago
Jan 03, 2022
Sell 2.42 M USD
Brophy Gerard
EVP, Biopharma Production
- 59418
40.77 USD
2 years ago
Jan 05, 2022
Sell 446 K USD
Brophy Gerard
EVP, Biopharma Production
- 11551
38.65 USD
2 years ago
Dec 27, 2021
Sell 424 K USD
Couturier Christophe
EVP, AMEA
- 10184
41.63 USD
2 years ago
Dec 21, 2021
Sell 1.57 M USD
Couturier Christophe
EVP, AMEA
- 38309
41 USD
2 years ago
Dec 22, 2021
Sell 1.17 M USD
Couturier Christophe
EVP, AMEA
- 28125
41.53 USD
2 years ago
Dec 08, 2021
Sell 233 K USD
Couturier Christophe
EVP, AMEA
- 5828
40 USD
2 years ago
Dec 09, 2021
Sell 316 K USD
Couturier Christophe
EVP, AMEA
- 7859
40.24 USD
2 years ago
Dec 01, 2021
Sell 3.93 M USD
GUPTA RAJIV
Director
- 100000
39.3 USD
3 years ago
Nov 12, 2021
Sell 3.06 M USD
Vanderhaegen Frederic
EVP, Europe
- 80000
38.25 USD
3 years ago
Nov 11, 2021
Sell 2.34 M USD
Vanderhaegen Frederic
EVP, Europe
- 60804
38.41 USD
3 years ago
Nov 01, 2021
Sell 4.03 M USD
GUPTA RAJIV
Director
- 100000
40.31 USD
3 years ago
Oct 01, 2021
Sell 3.99 M USD
GUPTA RAJIV
Director
- 100000
39.94 USD
3 years ago
Sep 20, 2021
Sell 5.99 M USD
Stubblefield Michael
President and CEO
- 141300
42.37 USD
3 years ago
Sep 01, 2021
Sell 3.95 M USD
GUPTA RAJIV
Director
- 100000
39.45 USD
3 years ago
Aug 26, 2021
Sell 697 K USD
Eck Steven W
SVP & Chief Accounting Officer
- 17383
40.08 USD
3 years ago
Aug 20, 2021
Sell 3.88 M USD
GUPTA RAJIV
Director
- 100000
38.81 USD
3 years ago
Jul 12, 2021
Bought 10.9 K USD
Natauri Jo
Director
+ 300
36.334 USD
3 years ago
Jul 30, 2021
Sell 3.02 M USD
Brophy Gerard
EVP, Biopharma Production
- 81125
37.24 USD
3 years ago
Jul 20, 2021
Sell 226 K USD
Bramwell James
EVP, Strategic Partners
- 6112
37 USD
3 years ago
Jul 09, 2021
Sell 217 K USD
Bramwell James
EVP, Strategic Partners
- 6110
35.56 USD
3 years ago
Jul 09, 2021
Sell 436 K USD
Bramwell James
EVP, Strategic Partners
- 12221
35.64 USD
3 years ago
Jun 28, 2021
Sell 1 M USD
Couturier Christophe
EVP, AMEA
- 28096
35.73 USD
3 years ago
Jun 25, 2021
Sell 2.42 M USD
GUPTA RAJIV
Director
- 68605
35.32 USD
3 years ago
Jun 08, 2021
Sell 4.89 M USD
Stubblefield Michael
President and CEO
- 152643
32.04 USD
3 years ago
Jun 09, 2021
Sell 7.53 M USD
Stubblefield Michael
President and CEO
- 235170
32.03 USD
3 years ago
Jun 10, 2021
Sell 1.86 M USD
Stubblefield Michael
President and CEO
- 57375
32.48 USD
3 years ago
May 26, 2021
Sell 4.78 M USD
GUPTA RAJIV
Director
- 150000
31.89 USD
3 years ago
May 27, 2021
Sell 2.49 M USD
GUPTA RAJIV
Director
- 78109
31.94 USD
3 years ago
May 27, 2021
Sell 3.2 M USD
Ohri Devashish
EVP, IMEA
- 100000
31.99 USD
3 years ago
May 26, 2021
Sell 478 K USD
Ohri Devashish
EVP, IMEA
- 15000
31.87 USD
3 years ago
May 24, 2021
Sell 5.71 M USD
GUPTA RAJIV
Director
- 180000
31.74 USD
3 years ago
May 24, 2021
Sell 4.97 M USD
GUPTA RAJIV
Director
- 157571
31.57 USD
3 years ago
May 24, 2021
Sell 290 K USD
Ohri Devashish
EVP, IMEA
- 9124
31.75 USD
3 years ago
May 21, 2021
Sell 581 K USD
Wondrasch Michael
EVP & CIO
- 18488
31.41 USD
3 years ago
May 20, 2021
Sell 575 K USD
Miller Justin
EVP & General Counsel
- 18488
31.12 USD
3 years ago
May 20, 2021
Sell 779 K USD
Couturier Christophe
EVP, AMEA
- 25010
31.13 USD
3 years ago
May 20, 2021
Sell 610 K USD
Brophy Gerard
EVP, Biopharma Production
- 19603
31.1 USD
3 years ago
May 11, 2021
Sell 80.6 M USD
Natauri Jo
Director
- 2626771
30.68 USD
5 years ago
Sep 09, 2019
Bought 2.46 M USD
Natauri Jo
Director
+ 149694
16.4566 USD
5 years ago
Sep 06, 2019
Bought 1.11 M USD
Natauri Jo
Director
+ 67437
16.5133 USD
5 years ago
Sep 06, 2019
Bought 840 K USD
Natauri Jo
Director
+ 49200
17.0639 USD
5 years ago
Aug 12, 2019
Bought 268 K USD
Natauri Jo
Director
+ 16245
16.5133 USD
5 years ago
Sep 25, 2019
Bought 147 K USD
Natauri Jo
Director
+ 9922
14.8 USD
5 years ago
Sep 25, 2019
Bought 76.4 K USD
Natauri Jo
Director
+ 5164
14.79 USD
5 years ago
Sep 25, 2019
Bought 61.2 K USD
Natauri Jo
Director
+ 4146
14.76 USD
5 years ago
Sep 25, 2019
Bought 56.2 K USD
Natauri Jo
Director
+ 3800
14.78 USD
5 years ago
Sep 09, 2019
Sell 2.46 M USD
Natauri Jo
Director
- 149694
16.4566 USD
5 years ago
Sep 25, 2019
Bought 26 K USD
Natauri Jo
Director
+ 1768
14.7 USD
5 years ago
Sep 25, 2019
Bought 1.48 K USD
Natauri Jo
Director
+ 100
14.775 USD
5 years ago
Sep 25, 2019
Bought 1.48 K USD
Natauri Jo
Director
+ 100
14.785 USD
5 years ago
Sep 25, 2019
Sell 76.4 K USD
Natauri Jo
Director
- 5164
14.79 USD
5 years ago
Sep 25, 2019
Sell 147 K USD
Natauri Jo
Director
- 9922
14.8 USD
5 years ago
Sep 25, 2019
Sell 26 K USD
Natauri Jo
Director
- 1768
14.7 USD
5 years ago
Sep 25, 2019
Sell 61.2 K USD
Natauri Jo
Director
- 4146
14.76 USD
5 years ago
Sep 25, 2019
Sell 1.48 K USD
Natauri Jo
Director
- 100
14.775 USD
5 years ago
Sep 25, 2019
Sell 56.2 K USD
Natauri Jo
Director
- 3800
14.78 USD
5 years ago
Sep 25, 2019
Sell 1.48 K USD
Natauri Jo
Director
- 100
14.785 USD
5 years ago
Aug 12, 2019
Bought 150 USD
Natauri Jo
Director
+ 9
16.66 USD
5 years ago
Aug 12, 2019
Sell 150 USD
Natauri Jo
Director
- 9
16.66 USD
5 years ago
Aug 12, 2019
Sell 268 K USD
Natauri Jo
Director
- 16245
16.5133 USD
5 years ago
Sep 06, 2019
Sell 840 K USD
Natauri Jo
Director
- 49200
17.0639 USD
5 years ago
Sep 06, 2019
Sell 1.11 M USD
Natauri Jo
Director
- 67437
16.5133 USD
5 years ago
Aug 06, 2019
Bought 1.47 K USD
Natauri Jo
Director
+ 88
16.66 USD
5 years ago
Aug 06, 2019
Sell 1.47 K USD
Natauri Jo
Director
- 88
16.66 USD
5 years ago
Jul 31, 2019
Bought 965 USD
Natauri Jo
Director
+ 55
17.5476 USD
5 years ago
Jul 31, 2019
Sell 965 USD
Natauri Jo
Director
- 55
17.5476 USD
5 years ago
May 17, 2019
Bought 183 K USD
Natauri Jo
Director
+ 13099
14 USD
5 years ago
May 17, 2019
Sell 197 K USD
Natauri Jo
Director
- 14049
14 USD
5 years ago
Sep 09, 2019
Bought 2.46 M USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 149694
16.4566 USD
5 years ago
Sep 06, 2019
Bought 1.11 M USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 67437
16.5133 USD
5 years ago
Sep 06, 2019
Bought 840 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 49200
17.0639 USD
5 years ago
Aug 12, 2019
Bought 268 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 16245
16.5133 USD
5 years ago
Sep 25, 2019
Bought 147 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 9922
14.8 USD
5 years ago
Sep 25, 2019
Bought 76.4 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 5164
14.79 USD
5 years ago
Sep 25, 2019
Bought 61.2 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 4146
14.76 USD
5 years ago
Sep 25, 2019
Bought 56.2 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 3800
14.78 USD
5 years ago
Sep 09, 2019
Sell 2.46 M USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 149694
16.4566 USD
5 years ago
Sep 25, 2019
Bought 26 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 1768
14.7 USD
5 years ago
Sep 25, 2019
Bought 1.48 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 100
14.785 USD
5 years ago
Sep 25, 2019
Bought 1.48 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 100
14.775 USD
5 years ago
Sep 25, 2019
Sell 147 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 9922
14.8 USD
5 years ago
Sep 25, 2019
Sell 26 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 1768
14.7 USD
5 years ago
Sep 25, 2019
Sell 61.2 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 4146
14.76 USD
5 years ago
Sep 25, 2019
Sell 1.48 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 100
14.775 USD
5 years ago
Sep 25, 2019
Sell 56.2 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 3800
14.78 USD
5 years ago
Sep 25, 2019
Sell 1.48 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 100
14.785 USD
5 years ago
Sep 25, 2019
Sell 76.4 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 5164
14.79 USD
5 years ago
Aug 12, 2019
Bought 150 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 9
16.66 USD
5 years ago
Aug 12, 2019
Sell 268 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 16245
16.5133 USD
5 years ago
Aug 12, 2019
Sell 150 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 9
16.66 USD
5 years ago
Sep 06, 2019
Sell 840 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 49200
17.0639 USD
5 years ago
Sep 06, 2019
Sell 1.11 M USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 67437
16.5133 USD
5 years ago
Aug 06, 2019
Bought 1.47 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 88
16.66 USD
5 years ago
Aug 06, 2019
Sell 1.47 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 88
16.66 USD
5 years ago
Jul 31, 2019
Bought 965 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 55
17.5476 USD
5 years ago
Jul 31, 2019
Sell 965 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 55
17.5476 USD
5 years ago
May 17, 2019
Bought 183 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 13099
14 USD
5 years ago
May 17, 2019
Sell 197 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 14049
14 USD
5 years ago
Sep 09, 2019
Bought 2.46 M USD
Connolly Thomas
Director
+ 149694
16.4566 USD
5 years ago
Sep 06, 2019
Bought 1.11 M USD
Connolly Thomas
Director
+ 67437
16.5133 USD
5 years ago
Sep 06, 2019
Bought 840 K USD
Connolly Thomas
Director
+ 49200
17.0639 USD
5 years ago
Aug 12, 2019
Bought 268 K USD
Connolly Thomas
Director
+ 16245
16.5133 USD
5 years ago
Sep 25, 2019
Bought 147 K USD
Connolly Thomas
Director
+ 9922
14.8 USD
5 years ago
Sep 25, 2019
Bought 76.4 K USD
Connolly Thomas
Director
+ 5164
14.79 USD
5 years ago
Sep 25, 2019
Bought 61.2 K USD
Connolly Thomas
Director
+ 4146
14.76 USD
5 years ago
Sep 25, 2019
Bought 56.2 K USD
Connolly Thomas
Director
+ 3800
14.78 USD
5 years ago
Sep 09, 2019
Sell 2.46 M USD
Connolly Thomas
Director
- 149694
16.4566 USD
5 years ago
Sep 25, 2019
Bought 26 K USD
Connolly Thomas
Director
+ 1768
14.7 USD
5 years ago
Sep 25, 2019
Bought 1.48 K USD
Connolly Thomas
Director
+ 100
14.775 USD
5 years ago
Sep 25, 2019
Bought 1.48 K USD
Connolly Thomas
Director
+ 100
14.785 USD
5 years ago
Sep 25, 2019
Sell 76.4 K USD
Connolly Thomas
Director
- 5164
14.79 USD
5 years ago
Sep 25, 2019
Sell 147 K USD
Connolly Thomas
Director
- 9922
14.8 USD
5 years ago
Sep 25, 2019
Sell 26 K USD
Connolly Thomas
Director
- 1768
14.7 USD
5 years ago
Sep 25, 2019
Sell 61.2 K USD
Connolly Thomas
Director
- 4146
14.76 USD
5 years ago
Sep 25, 2019
Sell 1.48 K USD
Connolly Thomas
Director
- 100
14.775 USD
5 years ago
Sep 25, 2019
Sell 56.2 K USD
Connolly Thomas
Director
- 3800
14.78 USD
5 years ago
Sep 25, 2019
Sell 1.48 K USD
Connolly Thomas
Director
- 100
14.785 USD
5 years ago
Aug 12, 2019
Bought 150 USD
Connolly Thomas
Director
+ 9
16.66 USD
5 years ago
Aug 12, 2019
Sell 150 USD
Connolly Thomas
Director
- 9
16.66 USD
5 years ago
Aug 12, 2019
Sell 268 K USD
Connolly Thomas
Director
- 16245
16.5133 USD
5 years ago
Sep 06, 2019
Sell 840 K USD
Connolly Thomas
Director
- 49200
17.0639 USD
5 years ago
Sep 06, 2019
Sell 1.11 M USD
Connolly Thomas
Director
- 67437
16.5133 USD
5 years ago
Aug 06, 2019
Bought 1.47 K USD
Connolly Thomas
Director
+ 88
16.66 USD
5 years ago
Aug 06, 2019
Sell 1.47 K USD
Connolly Thomas
Director
- 88
16.66 USD
5 years ago
Jul 31, 2019
Bought 965 USD
Connolly Thomas
Director
+ 55
17.5476 USD
5 years ago
Jul 31, 2019
Sell 965 USD
Connolly Thomas
Director
- 55
17.5476 USD
5 years ago
May 17, 2019
Bought 183 K USD
Connolly Thomas
Director
+ 13099
14 USD
5 years ago
May 17, 2019
Sell 197 K USD
Connolly Thomas
Director
- 14049
14 USD
4 years ago
Jun 18, 2020
Bought 10.8 K USD
Connolly Thomas
Director
+ 630
17.18 USD
4 years ago
Jun 18, 2020
Sell 10.8 K USD
Connolly Thomas
Director
- 630
17.18 USD
3 years ago
Apr 30, 2021
Sell 1.75 M USD
Ohri Devashish
EVP, IMEA
- 53649
32.58 USD
3 years ago
Apr 12, 2021
Sell 3.24 M USD
Ohri Devashish
EVP, IMEA
- 100160
32.37 USD
3 years ago
Apr 12, 2021
Sell 318 K USD
Vanderhaegen Frederic
EVP, Europe
- 10000
31.75 USD
3 years ago
Apr 12, 2021
Sell 543 K USD
Vanderhaegen Frederic
EVP, Europe
- 17075
31.83 USD
3 years ago
Apr 12, 2021
Sell 80.2 K USD
Bramwell James
EVP, Strategic Partners
- 2505
32 USD
3 years ago
Apr 12, 2021
Sell 3.32 M USD
Miller Justin
EVP & General Counsel
- 100000
33.21 USD
3 years ago
Apr 12, 2021
Sell 91.9 K USD
Miller Justin
EVP & General Counsel
- 2895
31.75 USD
3 years ago
Mar 09, 2021
Sell 282 K USD
Vanderhaegen Frederic
EVP, Europe
- 10000
28.21 USD
3 years ago
Mar 02, 2021
Sell 87.2 K USD
Wondrasch Michael
EVP & CIO
- 3036
28.71 USD
3 years ago
Feb 24, 2021
Sell 85.4 K USD
Brophy Gerard
EVP, Biopharma Production
- 3059
27.93 USD
3 years ago
Feb 22, 2021
Sell 566 K USD
Brophy Gerard
EVP, Biopharma Production
- 19769
28.62 USD
3 years ago
Feb 05, 2021
Sell 1.19 M USD
Wondrasch Michael
EVP & CIO
- 40000
29.77 USD
3 years ago
Jan 11, 2021
Sell 75.2 K USD
Bramwell James
EVP, Strategic Partners
- 2505
30 USD
3 years ago
Jan 11, 2021
Sell 6.51 M USD
Brophy Gerard
EVP, Biopharma Production
- 216332
30.08 USD
3 years ago
Jan 11, 2021
Sell 4.87 M USD
Brophy Gerard
EVP, Biopharma Production
- 162248
30.04 USD
3 years ago
Jan 06, 2021
Sell 314 K USD
Brophy Gerard
EVP, Biopharma Production
- 11509
27.24 USD
3 years ago
Jan 04, 2021
Sell 1.65 M USD
Brophy Gerard
EVP, Biopharma Production
- 59418
27.84 USD
3 years ago
Dec 21, 2020
Sell 272 K USD
Bramwell James
EVP, Strategic Partners
- 10020
27.14 USD
3 years ago
Dec 11, 2020
Sell 381 K USD
Shaw Christi
Director
- 14286
26.68 USD
3 years ago
Dec 07, 2020
Sell 2.7 M USD
Stubblefield Michael
President and CEO
- 98452
27.45 USD
3 years ago
Dec 04, 2020
Sell 11.2 M USD
Stubblefield Michael
President and CEO
- 412188
27.08 USD
4 years ago
Jun 30, 2020
Bought 6.8 K USD
Natauri Jo
Director
+ 400
17 USD
4 years ago
Jul 01, 2020
Bought 11 K USD
Natauri Jo
Director
+ 646
16.99 USD
4 years ago
Jun 30, 2020
Bought 9.99 K USD
Natauri Jo
Director
+ 584
17.1 USD
4 years ago
Jun 30, 2020
Bought 32.7 K USD
Natauri Jo
Director
+ 1910
17.1 USD
4 years ago
Jun 30, 2020
Sell 6.8 K USD
Natauri Jo
Director
- 400
17 USD
4 years ago
Jun 30, 2020
Bought 961 USD
Natauri Jo
Director
+ 56
17.16 USD
4 years ago
Jun 30, 2020
Bought 18.9 K USD
Natauri Jo
Director
+ 1103
17.1 USD
4 years ago
Jun 11, 2020
Bought 34.8 K USD
Natauri Jo
Director
+ 2055
16.92 USD
4 years ago
Jun 30, 2020
Sell 62.5 K USD
Natauri Jo
Director
- 3653
17.1 USD
4 years ago
Jun 25, 2020
Bought 2.54 K USD
Natauri Jo
Director
+ 151
16.84 USD
4 years ago
Jun 25, 2020
Sell 2.54 K USD
Natauri Jo
Director
- 151
16.84 USD
4 years ago
Jun 23, 2020
Bought 5.32 K USD
Natauri Jo
Director
+ 300
17.75 USD
4 years ago
Jun 19, 2020
Bought 35.9 USD
Natauri Jo
Director
+ 2
17.95 USD
4 years ago
Jun 19, 2020
Sell 35.9 USD
Natauri Jo
Director
- 2
17.95 USD
4 years ago
Jun 22, 2020
Bought 504 USD
Natauri Jo
Director
+ 29
17.38 USD
4 years ago
Jun 18, 2020
Bought 119 K USD
Natauri Jo
Director
+ 6798
17.51 USD
4 years ago
Jun 22, 2020
Sell 504 USD
Natauri Jo
Director
- 29
17.38 USD
4 years ago
Jun 23, 2020
Sell 5.32 K USD
Natauri Jo
Director
- 300
17.75 USD
4 years ago
Jun 26, 2020
Bought 336 USD
Natauri Jo
Director
+ 20
16.82 USD
4 years ago
Jun 26, 2020
Sell 336 USD
Natauri Jo
Director
- 20
16.82 USD
4 years ago
Jun 12, 2020
Bought 5.09 K USD
Natauri Jo
Director
+ 300
16.98 USD
4 years ago
Jun 11, 2020
Sell 34.8 K USD
Natauri Jo
Director
- 2055
16.92 USD
4 years ago
Jun 12, 2020
Sell 5.09 K USD
Natauri Jo
Director
- 300
16.98 USD
4 years ago
Jul 01, 2020
Bought 5.9 K USD
Natauri Jo
Director
+ 347
16.99 USD
4 years ago
Jul 01, 2020
Bought 7.41 K USD
Natauri Jo
Director
+ 436
16.99 USD
4 years ago
Jul 01, 2020
Sell 170 K USD
Natauri Jo
Director
- 10000
17 USD
4 years ago
Jun 18, 2020
Sell 119 K USD
Natauri Jo
Director
- 6798
17.51 USD
4 years ago
Jul 01, 2020
Sell 34.1 K USD
Natauri Jo
Director
- 2006
16.99 USD
4 years ago
Jul 01, 2020
Bought 1.05 K USD
Natauri Jo
Director
+ 62
16.99 USD
4 years ago
Jul 01, 2020
Sell 229 K USD
Natauri Jo
Director
- 13404
17.09 USD
4 years ago
Jun 18, 2020
Bought 10.8 K USD
Natauri Jo
Director
+ 630
17.18 USD
4 years ago
Jun 18, 2020
Sell 10.8 K USD
Natauri Jo
Director
- 630
17.18 USD
4 years ago
Jun 30, 2020
Bought 6.8 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 400
17 USD
4 years ago
Jul 01, 2020
Bought 11 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 646
16.99 USD
4 years ago
Jun 30, 2020
Bought 9.99 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 584
17.1 USD
4 years ago
Jun 30, 2020
Bought 32.7 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 1910
17.1 USD
4 years ago
Jun 30, 2020
Sell 6.8 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 400
17 USD
7. News
Avantor® Opens New Bridgewater Innovation Center Focused on Solving Life Science's Biggest Challenges RADNOR, Pa. , Nov. 14, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its new flagship Bridgewater Innovation Center. prnewswire.com - 2 days ago
MD vs. AVTR: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Pediatrix Medical Group (MD) or Avantor, Inc. (AVTR). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 1 week ago
Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors RADNOR, Pa. , Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D. prnewswire.com - 1 week ago
Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down Despite AVTR's continued stability in the Education and Advanced Technology end markets, it reports an overall soft third-quarter performance. zacks.com - 2 weeks ago
Avantor Inc. (AVTR) Q3 2024 Earnings Call Transcript Avantor Inc. (NYSE:AVTR ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President and Chief Executive Officer Brent Jones - Executive Vice President and Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Douglas Schenkel - Wolfe Research Tycho Peterson - Jefferies Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Daniel Leonard - UBS Conor McNamara - RBC Capital Markets Daniel Arias - Stifel Rachel Vatnsdal - JP Morgan Luke Sergott - Barclays Tejas Savant - Morgan Stanley Operator Good morning. My name is Emily, and I will be your conference operator today. seekingalpha.com - 3 weeks ago
Avantor (AVTR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Avantor (AVTR) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 3 weeks ago
Avantor, Inc. (AVTR) Beats Q3 Earnings Estimates Avantor, Inc. (AVTR) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.25 per share a year ago. zacks.com - 3 weeks ago
Avantor® Reports Third Quarter 2024 Results Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 million Diluted GAAP EPS of $0.08; adjusted EPS of $0.26 Operating cash flow of $244.8 million; free cash flow of $204.0 million RADNOR, Pa. , Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. prnewswire.com - 3 weeks ago
Avantor® Strengthens Partnership with National Institute for Bioprocessing Research and Training (NIBRT) to Address Critical Biopharma Industry Challenges Avantor and NIBRT have formed a new partnership to supply advanced Masterflex® equipment, essential products, and expert training to foster innovations in biopharma manufacturing RADNOR, Pa. , Oct. 23, 2024  /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced an expanded partnership with the National Institute for Bioprocessing Research and Training (NIBRT). prnewswire.com - 3 weeks ago
AVTR Stock Flat Following the Close of Divestiture Deal With Audax Avantor closes its deal with Audax to divest its clinical services business. zacks.com - 3 weeks ago
Audax Private Equity Completes Carveout of Avantor, Inc.'s Clinical Services Business and Rebrands the Company as Resonant Clinical Solutions SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Audax Private Equity (“Audax”) has completed its acquisition of the clinical services business of Avantor, Inc. (NYSE: AVTR) and, in close collaboration with the employees, has re-branded the business as Resonant Clinical Solutions (“Resonant” or “the Company”). Resonant is comprised of three well-respected brands – EPL Archives, MESM, and Therapak. These long-standing brands, whose roots and lineage extend as far back as the 1970s, provide a comprehensi. businesswire.com - 4 weeks ago
Avantor® Closes Previously Announced Divestiture of its Clinical Services Business RADNOR, Pa. , Oct. 18, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it has closed the divestiture of its clinical services business to Audax Private Equity in a transaction valued at approximately $650 million. prnewswire.com - 4 weeks ago
8. Profile Summary

Avantor, Inc. AVTR

image
COUNTRY US
INDUSTRY Chemicals - Specialty
MARKET CAP $ 14.1 B
Dividend Yield 0.00%
Description Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Contact Radnor Corporate Center, Radnor, PA, 19087 https://www.avantorsciences.com
IPO Date May 17, 2019
Employees 14500
Officers Christina Jones Vice President of Investor Relations Ms. Kitty Sahin Executive Vice President of Strategy & Corporate Development Ms. Brittany Hankamer Executive Vice President & Chief HR Officer Mr. R. Brent Jones Executive Vice President & Chief Financial Officer Mr. Michael Stubblefield President, Chief Executive Officer & Director Mr. Steven W. Eck Senior Vice President, Corporate Controller & Chief Accounting Officer Mr. James Bramwell Executive Vice President of Sales & Customer Excellence Mr. Michael Wondrasch Executive Vice President & Chief Information Officer Mr. Claudius O. Sokenu Executive Vice President, Corporate Secretary and Chief Legal & Compliance Officer Ms. Allison K. Hosak Senior Vice President of Global Communications & Brand